JP7111722B2 - 抗がん剤およびその調製方法 - Google Patents
抗がん剤およびその調製方法 Download PDFInfo
- Publication number
- JP7111722B2 JP7111722B2 JP2019537750A JP2019537750A JP7111722B2 JP 7111722 B2 JP7111722 B2 JP 7111722B2 JP 2019537750 A JP2019537750 A JP 2019537750A JP 2019537750 A JP2019537750 A JP 2019537750A JP 7111722 B2 JP7111722 B2 JP 7111722B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- mmol
- compounds
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662398783P | 2016-09-23 | 2016-09-23 | |
| US62/398,783 | 2016-09-23 | ||
| PCT/US2017/052967 WO2018057897A1 (en) | 2016-09-23 | 2017-09-22 | Anti-cancer agents and preparation thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529563A JP2019529563A (ja) | 2019-10-17 |
| JP2019529563A5 JP2019529563A5 (enExample) | 2020-11-05 |
| JP7111722B2 true JP7111722B2 (ja) | 2022-08-02 |
Family
ID=61690726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537750A Active JP7111722B2 (ja) | 2016-09-23 | 2017-09-22 | 抗がん剤およびその調製方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10858371B2 (enExample) |
| EP (1) | EP3515492B1 (enExample) |
| JP (1) | JP7111722B2 (enExample) |
| KR (1) | KR102646702B1 (enExample) |
| CN (1) | CN109862916A (enExample) |
| AU (1) | AU2017331260B2 (enExample) |
| BR (1) | BR112019005885A2 (enExample) |
| CA (1) | CA3037883A1 (enExample) |
| DK (1) | DK3515492T3 (enExample) |
| IL (1) | IL265521B2 (enExample) |
| MA (1) | MA46291A (enExample) |
| MX (1) | MX394670B (enExample) |
| RU (1) | RU2019111768A (enExample) |
| WO (1) | WO2018057897A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017331260B2 (en) | 2016-09-23 | 2024-11-07 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080096879A1 (en) | 2006-09-08 | 2008-04-24 | University Of Pittsburgh-- Of The Commonwealth System Of Higher Education | Synthesis of fr901464 and analogs with antitumor activity |
| WO2009031999A1 (en) | 2007-09-07 | 2009-03-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Fr901464 and analogs with antitumor activity and method for their preparation |
| US20110178098A1 (en) | 2008-06-21 | 2011-07-21 | Webb Thomas R | Anticancer compounds and methods of making and using same |
| WO2014158242A1 (en) | 2013-03-13 | 2014-10-02 | Golden Biotechnology Corporation | Method for the treatment of fatty liver disease |
| WO2015077370A1 (en) | 2013-11-19 | 2015-05-28 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
| US20150307512A1 (en) | 2012-12-21 | 2015-10-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Synthesis of fr901464 and analogs with antitumor activity |
| JP2015535004A (ja) | 2012-11-05 | 2015-12-07 | ファイザー・インク | スプライソスタチン類似体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901464A (fr) | 1943-01-23 | 1945-07-27 | Boehringer & Soehne Gmbh | Procédé d'obtention de vanilline |
| CN101417934B (zh) * | 2007-10-24 | 2012-04-18 | 国鼎生物科技股份有限公司 | 分离自牛樟芝萃取物的化合物 |
| NZ587706A (en) | 2008-03-18 | 2012-12-21 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| US20150025017A1 (en) * | 2012-02-28 | 2015-01-22 | Fred Hutchinson Cancer Research Center | Compositions and methods for treating cancer |
| CN105611930B (zh) | 2013-07-15 | 2021-03-02 | 亥姆霍兹慕尼黑中心-德国环境与健康研究中心（股份有限公司） | 作为非凋亡调控性细胞死亡抑制剂的螺环喹喔啉衍生物 |
| KR102092569B1 (ko) * | 2013-09-17 | 2020-03-25 | 엘지디스플레이 주식회사 | 터치 스크린 일체형 디스플레이 장치와 이의 구동 방법 |
| EP3468976A4 (en) * | 2016-06-08 | 2019-11-27 | William Marsh Rice University | DERIVATIVES OF THAILANSTATIN A, METHOD FOR THE TREATMENT AND METHOD FOR SYNTHESIS THEREOF |
| AU2017331260B2 (en) | 2016-09-23 | 2024-11-07 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
-
2017
- 2017-09-22 AU AU2017331260A patent/AU2017331260B2/en active Active
- 2017-09-22 KR KR1020197011144A patent/KR102646702B1/ko active Active
- 2017-09-22 MX MX2019003368A patent/MX394670B/es unknown
- 2017-09-22 RU RU2019111768A patent/RU2019111768A/ru unknown
- 2017-09-22 DK DK17853991.2T patent/DK3515492T3/da active
- 2017-09-22 IL IL265521A patent/IL265521B2/en unknown
- 2017-09-22 CN CN201780065546.7A patent/CN109862916A/zh active Pending
- 2017-09-22 CA CA3037883A patent/CA3037883A1/en active Pending
- 2017-09-22 BR BR112019005885-0A patent/BR112019005885A2/pt unknown
- 2017-09-22 US US16/335,378 patent/US10858371B2/en active Active
- 2017-09-22 MA MA046291A patent/MA46291A/fr unknown
- 2017-09-22 JP JP2019537750A patent/JP7111722B2/ja active Active
- 2017-09-22 WO PCT/US2017/052967 patent/WO2018057897A1/en not_active Ceased
- 2017-09-22 EP EP17853991.2A patent/EP3515492B1/en active Active
-
2020
- 2020-11-09 US US17/092,829 patent/US11851441B2/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080096879A1 (en) | 2006-09-08 | 2008-04-24 | University Of Pittsburgh-- Of The Commonwealth System Of Higher Education | Synthesis of fr901464 and analogs with antitumor activity |
| WO2009031999A1 (en) | 2007-09-07 | 2009-03-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Fr901464 and analogs with antitumor activity and method for their preparation |
| US20110178098A1 (en) | 2008-06-21 | 2011-07-21 | Webb Thomas R | Anticancer compounds and methods of making and using same |
| JP2015535004A (ja) | 2012-11-05 | 2015-12-07 | ファイザー・インク | スプライソスタチン類似体 |
| US20150307512A1 (en) | 2012-12-21 | 2015-10-29 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Synthesis of fr901464 and analogs with antitumor activity |
| WO2014158242A1 (en) | 2013-03-13 | 2014-10-02 | Golden Biotechnology Corporation | Method for the treatment of fatty liver disease |
| WO2015077370A1 (en) | 2013-11-19 | 2015-05-28 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
Non-Patent Citations (5)
| Title |
|---|
| Chemistry - A European Journal，2011年，17(3)，P.895-904 |
| Heterocycles，2004年，64，P.51-56 |
| Journal of Natural Products，2014年，77(8)，P.1864-1870 |
| Organic Letters，16(23)，2014年，P.6200-6203 |
| Tetrahedron，2006年，62(7)，P.1378-1389 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102646702B1 (ko) | 2024-03-11 |
| RU2019111768A (ru) | 2020-10-23 |
| IL265521A (en) | 2019-05-30 |
| IL265521B1 (en) | 2024-05-01 |
| WO2018057897A1 (en) | 2018-03-29 |
| IL265521B2 (en) | 2024-09-01 |
| US20190218228A1 (en) | 2019-07-18 |
| MA46291A (fr) | 2019-07-31 |
| US20210395265A1 (en) | 2021-12-23 |
| AU2017331260A1 (en) | 2019-05-16 |
| EP3515492A1 (en) | 2019-07-31 |
| CN109862916A (zh) | 2019-06-07 |
| JP2019529563A (ja) | 2019-10-17 |
| MX2019003368A (es) | 2019-09-16 |
| AU2017331260B2 (en) | 2024-11-07 |
| BR112019005885A2 (pt) | 2020-06-02 |
| CA3037883A1 (en) | 2018-03-29 |
| RU2019111768A3 (enExample) | 2020-11-24 |
| EP3515492B1 (en) | 2023-07-26 |
| KR20190077340A (ko) | 2019-07-03 |
| US11851441B2 (en) | 2023-12-26 |
| MX394670B (es) | 2025-03-11 |
| US10858371B2 (en) | 2020-12-08 |
| EP3515492A4 (en) | 2020-04-08 |
| DK3515492T3 (da) | 2023-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109665968B (zh) | 并环化合物及其制备方法和用途 | |
| JP6873221B2 (ja) | ベンズアミド及びニコチンアミド化合物及びこれを使用する方法 | |
| JP6929903B2 (ja) | 抗癌剤およびその調製方法 | |
| UA75716C2 (en) | Thiopene- and thiazolesulfonamides as antineoplastic agents, pharmaceutical composition based thereon | |
| JP6622290B2 (ja) | Ｈｉｖ−１プロテアーゼ阻害剤およびその用途 | |
| JP2024164181A (ja) | カリスポンジオリド、その類似体、およびそれらの使用 | |
| KR100915287B1 (ko) | 티아디아졸린 유도체 | |
| AU2020226633C1 (en) | Nurr1 receptor modulators | |
| CN101565409A (zh) | 哌嗪或高哌嗪草酰肼类化合物及其制备方法和用途 | |
| JP7098643B2 (ja) | Ｈｉｖ／ａｉｄｓに対する強力な三環式ｐ２リガンド含有ｈｉｖプロテアーゼ阻害剤 | |
| JP2019529563A (ja) | 抗がん剤およびその調製方法 | |
| CN103214486B (zh) | β-咔啉衍生物或可药用盐，其制备方法及其抗肿瘤的应用 | |
| HK40006497A (en) | Anti-cancer agents and preparation thereof | |
| HK40062614A (en) | Anti-cancer agents and preparation thereof | |
| CN105541696A (zh) | 一种抗肿瘤的化合物及其制备方法和应用 | |
| WO2024027695A1 (zh) | 作为her2抑制剂的化合物 | |
| JP2001524067A (ja) | 放射線感作性タキサン類およびその医薬製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20190703 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190703 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200915 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200915 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20210128 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20210721 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210811 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20211110 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220208 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220523 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220620 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220721 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7111722 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |